A Three Year, Prospective, Open-label, Study To Evaluate Clinical Efficacy, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
Latest Information Update: 12 Dec 2022
At a glance
- Drugs Atorvastatin (Primary)
- Indications Hyperlipoproteinaemia type II
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Pfizer; Viatris
- 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Mar 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 12 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.